Findings With Abemaciclib Plus Tamoxifen in Advanced Breast Cancer
Erika P. Hamilton, MD, discusses the results from a phase II study of abemaciclib plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.
Erika P. Hamilton, MD, director of the breast and gynecologic research program at Sarah Cannon Research Institute, discusses the results from a phase II study of abemaciclib (Verzenio) plus tamoxifen versus abemaciclib monotherapy in patients with HR-positive, HER2-negative advanced breast cancer.
The progression-free survival (PFS) range was 6.5 months to 9.1 months in this study and was not statistically significant across arms. Hamilton says the single-agent abemaciclib had equal activity in regard to PFS. Hamilton also noted the arm receiving 200 mg of abemaciclib had a response rate of 29% compared to 19% in the previous MONARCH trial.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
